Three Cases of Manifesting Female Carriers in Patients with Duchenne Muscular Dystrophy
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Duchenne muscular dystrophy usually affects males. However, females are also affected in rare instances. Approximately 8% of female Duchenne muscular dystrophy (DMD) carriers are manifesting carriers and have muscle weakness to some extent. We investigated the clinical features of 3 female patients with dystrophinopathy diagnosed by clinical, pathological, and genetic studies at our neuromuscular disease clinic. The onset age of manifesting symptoms varied (8-28 years). Muscle weakness grade varied as follows: patient 1 showed asymmetrical bilateral proximal upper and lower extremities weakness, patient 2 showed asymmetrical bilateral upper extremities weakness similar to scapulohumoral muscular dystrophy, and patient 3 had only bilateral asymmetric proximal lower extremities weakness. Two patients had familial histories of DMD (their sons were diagnosed with DMD), but the 1 remaining patient had no familial history of DMD. The serum creatine kinase level was elevated in all patients, but it was not correlated with muscular weakness. An electromyography study showed findings of myopathy in all patients. One patient was diagnosed with a DMD carrier by a muscle biopsy with an immunohistochemical stain (dystrophin). The remaining 2 patients with familial history of DMD were diagnosed by multiplex ligation-dependent probe amplification (MLPA). There were inconsistent clinical features in the female carriers. An immunohistochemical analysis of dystrophin could be useful for female carrier patients. Also, multiplex ligation-dependent probe amplification is essential for the diagnosis of a manifesting female carrier DMD in female myopathic patients because conventional multiplex PCR could not detect the duplication and is less accurate compared to MLPA.
Abstract
Duchenne muscular dystrophy usually affects males. However, females are also affected in rare instances. Approximately 8% of female Duchenne muscular dystrophy (DMD) carriers are manifesting carriers and have muscle weakness to some extent. We investigated the clinical features of 3 female patients with dystrophinopathy diagnosed by clinical, pathological, and genetic studies at our neuromuscular disease clinic. The onset age of manifesting symptoms varied (8-28 years). Muscle weakness grade varied as follows: patient 1 showed asymmetrical bilateral proximal upper and lower extremities weakness, patient 2 showed asymmetrical bilateral upper extremities weakness similar to scapulohumoral muscular dystrophy, and patient 3 had only bilateral asymmetric proximal lower extremities weakness. Two patients had familial histories of DMD (their sons were diagnosed with DMD), but the 1 remaining patient had no familial history of DMD. The serum creatine kinase level was elevated in all patients, but it was not correlated with muscular weakness. An electromyography study showed findings of myopathy in all patients. One patient was diagnosed with a DMD carrier by a muscle biopsy with an immunohistochemical stain (dystrophin). The remaining 2 patients with familial history of DMD were diagnosed by multiplex ligation-dependent probe amplification (MLPA). There were inconsistent clinical features in the female carriers. An immunohistochemical analysis of dystrophin could be useful for female carrier patients. Also, multiplex ligation-dependent probe amplification is essential for the diagnosis of a manifesting female carrier DMD in female myopathic patients because conventional multiplex PCR could not detect the duplication and is less accurate compared to MLPA.
참고문헌 (14)
- Walcher T, "Cardiac involvement in a female carrier of Duchenne muscular dystrophy", Int J Cardiol, 138, pp.302~305 (2010)
- Ceulemans BP, "Muscle pain as the only presenting symptom in a girl with dystrophinopathy", Pediatr Neurol, 38, pp.64~66 (2008)
- Hoffman EP, "Dystrophinopathy in isolated cases of myopathy in females", Neurology, 42, pp.967~975 (1992)
- Hoogerwaard EM, "Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study", Lancet, 353, pp.2116~2119 (1999)
- Griggs RC, "Clinical investigation in Duchenne dystrophy: V. Use of creatine kinase and pyruvate kinase in carrier detection", Muscle Nerve, 8, pp.60~67 (1985)
- Politano L, "Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies", JAMA, 275, pp.1335~1338 (1996)
- Lukasik E, "Electrocardiographic studies in female carriers of Duchenne muscular dystrophy", J Neurol, 209, pp.279~285 (1975)
- Hoffman EP, "Dystrophin: the protein product of the Duchenne muscular dystrophy locus", Cell, 51, pp.919~928 (1987)
- Arahata K, "Mosaic expression of dystrophin in symptomatic carriers of Duchenne’s muscular dystrophy", N Engl J Med, 320, pp.138~142 (1989)
- Chamberlain JS, "Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification", Nucleic Acids Res, 16, pp.11141~11156 (1988)
- Beggs AH, "Detection of 98% of DMD", BMD gene deletions by polymerase chain reaction, 1990, pp.86, 45~48
- Kunkel LM, "Searching for dystrophin gene deletions in patients with atypical presentations. In: Lindsten J, Petterson U, editors. Etiology of Human Diseases at the DNA Level", pp.51~60 (1991), Raven Press
- Schouten JP, "Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification", Nucleic Acids Res, 30, pp.e57~ (2002)
- Schwartz M, "Multiplex ligation-dependent probe amplification is superior for detecting deletions", duplications in Duchenne muscular dystrophy, 2005, pp.67, 189~191